A patient on a long-term medication can spend every year proving, again, that the drug is still needed. UnitedHealth says it has ended that step for a third of such cases. In its third-quarter results, the company says it eliminated 33% of drug reauthorizations, covering nearly 270 chronic-condition medications.
The company also says it plans to eliminate 30% of its current prior approval volume by the end of 2026. UnitedHealth describes both as its own commitments. They are not federal or state rules, and the company reported them alongside a raised profit outlook.
The reauthorizations UnitedHealth says are gone
UnitedHealth’s earnings release, filed October 13, lists the drug step under its drug affordability commitments. It says the company eliminated 33% of drug reauthorizations. Those reauthorizations, it says, represent 11% of pharmacy prior approvals.
A reauthorization is the repeat approval a plan can require for a drug a patient already takes. The first approval stays on the books, and the plan asks again after a set period. UnitedHealth says it has dropped the repeat request for nearly 270 chronic-condition medications. The release excerpt does not name them.
That is a narrower claim than it may sound. Eleven percent of pharmacy approvals is the slice these repeat requests make up, and a third of that slice is gone. The first approval for a new prescription is a different step, and the release says nothing about removing it.
For anyone on a maintenance drug through UnitedHealthcare, the practical task is to ask the plan or the pharmacy whether the medication is among the ones that no longer need repeat approval. Anyone whose drug still needs approval has a separate task: knowing what to do if the plan says no.
What changed this year: Social Security and Medicare change every year, and nobody sends you a memo. The Retirement Money Brief breaks down what changed and what to do.
Get the Retirement Money Brief →
We may earn a commission from links on this page.
What UnitedHealth promises by the end of 2026
The release’s “approval reform” section lists several targets for year-end. UnitedHealth says it plans to eliminate 30% of current prior approval volume by the end of 2026. It also says it will eliminate nearly two-thirds of prior approval requirements for pediatric care, with waivers for certain procedures at leading pediatric hospitals.
Another target is electronic submission. The company says more than 70% of UnitedHealthcare prior approvals should be included in standardized electronic submissions by the end of 2026. It also says it will report prior approval metrics publicly so clinicians and members can see how the process performs.
Expanded Gold Card eligibility and the removal of home health approvals are the third piece. A Gold Card exempts high-performing clinicians from routine approval requirements. The company says these two changes together eliminate nearly 10% of total UnitedHealthcare prior approval volume.
None of these bullets names Medicare Advantage, Medicare Part D or employer plans. They refer to UnitedHealthcare broadly, or to specific kinds of care such as pediatrics and home health. How much of the cut reaches any one member depends on the plan.
Promises, not rules
UnitedHealth Group Chief Executive Stephen Hemsley said in the release that the third-quarter results “reflect the discipline and execution our teams are bringing to every part of our business.” The release puts revenue at $112.7 billion and the medical care ratio at 88.4%, compared with 89.9% a year earlier.
The company raised its full-year outlook to at least $19.50 a share in GAAP earnings and at least $20.50 adjusted. The prior approval commitments sit in the same document as those figures. They are company statements of intent, with year-end targets. No regulator has ordered them.
The same release includes other member-facing commitments. UnitedHealth says more than 7 million members in employer-sponsored plans will be eligible for doula coverage by January 2027, and that it will rebate profits from its ACA individual plans in 2026 to about 1 million members. It says it will pass through 100% of manufacturer rebate discounts to clients by January 1, 2028.
If a drug still needs approval, the Medicare appeal clock
For members of Medicare drug plans, the government sets the appeal steps. Medicare.gov says a redetermination, the first appeal, must be filed within 65 days of the date on the plan’s denial notice. A late filer must give a reason.
The standard decision time is 7 days for a benefits appeal and 14 days for a payment appeal. A fast appeal takes 72 hours when the plan decides, or the prescriber tells the plan, that waiting could seriously jeopardize the patient’s health. An exception request needs a statement from the prescriber explaining the medical reason.
If the plan upholds the denial, the next level is an independent review entity, and Medicare.gov says to file within 60 days of the plan’s decision. Medicare’s appeals page adds that a State Health Insurance Assistance Program offers free counseling, at shiphelp.org.
The open question for anyone whose drug still needs approval is the one every denial letter raises. If the plan says no, who files the appeal, and by what date? The 65 days run from the date on the notice. The company’s promises do not change that clock.
Did a plan deny a prescription this fall?
A denial letter starts a 65-day clock for a Medicare drug appeal, and a fast appeal runs only 72 hours. A missed date or a missing prescriber statement can leave a patient paying out of pocket for a drug the plan should have covered.
The Medicare Cost & Coverage Protection Kit includes Part 4, Beat a Denial, which lays out the prior-authorization appeal steps. It also covers the 2026 Part D cap and the programs that pay Medicare premiums and cut drug bills.
Follow the prior-authorization appeal steps in the Medicare Cost & Coverage Protection Kit →
More Financial Reading
- 21 Ways to Stretch a $2,087 Social Security Check
- 15 Places to Find Your Share of the $4.25 Billion States Give Back
- 21 Ways Retirees Can Raise $1,000 Fast Without a Job
This article was produced with the assistance of AI and reviewed by the editorial team.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
